%0 Journal Article
%A Dorman, Klara
%A Auernhammer, Christoph J
%A Spitzweg, Christine
%A Schmidmaier, Ralf
%A Nölting, Svenja
%A Kroiss, Matthias
%A Reincke, Martin
%A Schulz, Christian
%A Angele, Martin
%A Werner, Jens
%A Schmid-Tannwald, Christine
%A Rauch, Josefine
%A Zacherl, Mathias
%A Knösel, Thomas
%A Kumbrink, Jörg
%A Jung, Andreas
%A Klauschen, Frederick
%A Tufman, Amanda
%A Zhang, Danmei
%A Weiss, Lena
%A Böck, Stefan
%A von Bergwelt-Baildon, Michael
%A Heinemann, Volker
%A Westphalen, C. Benedikt
%A Heinrich, Kathrin
%T Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.
%J Targeted oncology
%V 20
%N 4
%@ 1776-2596
%C Paris
%I Springer Verlag France S.A.R.L.
%M DKFZ-2025-01329
%P 715-724
%D 2025
%Z 2025 Jul;20(4):715-724
%X Comprehensive genomic profiling (CGP) has become more generally accessible to patients with rare cancer, but data on the results and benefits are limited.Our objective was to gain a real-world understanding of the molecular landscape and targeted treatment options in neuroendocrine tumors, neuroendocrine carcinomas, adrenocortical carcinomas, pheochromocytomas, and carcinoids.In this retrospective cohort study, we analyzed CGP results and clinical data from patients with neuroendocrine tumors, neuroendocrine carcinomas, adrenocortical carcinomas, pheochromocytomas, and carcinoids who were discussed in the CCCMunichLMU Molecular Tumor Board (MTB) between May 2017 and April 2023.In total, 104 patients with endocrine and neuroendocrine neoplasms were discussed in the MTB. CGP was technically successful in 99 patients. The most commonly mutated genes were TP53 (29.3
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40587033
%R 10.1007/s11523-025-01152-6
%U https://inrepo02.dkfz.de/record/302789